REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2014

Nov 25, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2014-11-24

Reporting Person: GILMAN ALFRED G (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-11-24	Common Stock	M	15000.0	$24.41	Acquired	15000	Direct
2014-11-24	Common Stock	M	15000.0	$33.42	Acquired	30000	Direct
2014-11-24	Common Stock	M	10000.0	$57.11	Acquired	40000	Direct
2014-11-24	Common Stock	S	4600.0	$405.65	Disposed	35400	Direct
2014-11-24	Common Stock	S	6327.0	$406.98	Disposed	29073	Direct
2014-11-24	Common Stock	S	9933.0	$407.93	Disposed	19140	Direct
2014-11-24	Common Stock	S	7500.0	$409.0	Disposed	11640	Direct
2014-11-24	Common Stock	S	7500.0	$410.05	Disposed	4140	Direct
2014-11-24	Common Stock	S	4140.0	$411.06	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-11-24	Non-Qualified Stock Option (right to buy)	$24.41	M	15000.0	Disposed	2020-01-04	Common Stock (15000)	Direct
2014-11-24	Non-Qualified Stock Option (right to buy)	$33.42	M	15000.0	Disposed	2021-01-03	Common Stock (15000)	Direct
2014-11-24	Non-Qualified Stock Option (right to buy)	$57.11	M	10000.0	Disposed	2022-01-03	Common Stock (10000)	Direct

Footnotes

F1: Represents volume-weighted average price of sales of 4,600 shares of Company stock on November 24, 2014 at prices ranging from $405.28 to $406.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 24, 2014 at each separate price.

F2: Represents volume-weighted average price of sales of 6,327 shares of Company stock on November 24, 2014 at prices ranging from $406.46 to $407.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 24, 2014 at each separate price.

F3: Represents volume-weighted average price of sales of 9,933 shares of Company stock on November 24, 2014 at prices ranging from $407.51 to $408.50. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 24, 2014 at each separate price.

F4: Represents volume-weighted average price of sales of 7,500 shares of Company stock on November 24, 2014 at prices ranging from $408.51 to $409.50. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 24, 2014 at each separate price.

F5: Represents volume-weighted average price of sales of 7,500 shares of Company stock on November 24, 2014 at prices ranging from $409.51 to $410.50. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 24, 2014 at each separate price.

F6: Represents volume-weighted average price of sales of 4,140 shares of Company stock on November 24, 2014 at prices ranging from $410.63 to $411.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 24, 2014 at each separate price.

F7: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.